



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 39/00	A2	(11) International Publication Number: WO 98/34640 (43) International Publication Date: 13 August 1998 (13.08.98)
(21) International Application Number: PCT/US98/02293 (22) International Filing Date: 3 February 1998 (03.02.98) (30) Priority Data: 60/037,854 7 February 1997 (07.02.97) US 9705040.5 12 March 1997 (12.03.97) GB (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SHIVER, John, W., Jr. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). DAVIES, Mary-Ellen, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). FREED, Daniel, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). LIU, Margaret, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PERRY, Helen, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> BEST AVAILABLE COPY
(54) Title: SYNTHETIC HIV GAG GENES (57) Abstract Synthetic DNA molecules encoding HIV <i>gag</i> and modifications of HIV <i>gag</i> are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against HIV infection through stimulation of neutralizing antibody and cell-mediated immunity.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION
SYNTHETIC HIV GAG GENES

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Not applicable

STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not applicable

10 REFERENCE TO MICROFICHE APPENDIX
Not applicable

FIELD OF INVENTION
HIV Vaccines.

15

BACKGROUND OF THE INVENTION

Human Immunodeficiency Virus-1 (HIV-1) is the etiological agent of acquired human immune deficiency syndrome (AIDS) and related disorders. HIV-1 is an RNA virus of the Retroviridae family and exhibits the 5'LTR-*gag-pol-env*-LTR3' organization of all retroviruses. In addition, HIV-1 comprises a handful of genes with regulatory or unknown functions, including the *tat* and *rev* genes. The *env* gene encodes the viral envelope glycoprotein that is translated as a 160-kilodalton (kDa) precursor (gp160) and then
20 cleaved by a cellular protease to yield the external 120-kDa envelope glycoprotein (gp120) and the transmembrane 41-kDa envelope glycoprotein (gp41). Gp120 and gp41 remain associated and are displayed on the viral particles and the surface of HIV-infected cells. Gp120 binds to the CD4 receptor present on the surface of helper T-
25 lymphocytes, macrophages and other target cells. After gp120 binds to CD4, gp41 mediates the fusion event responsible for virus entry.

Infection begins when gp120 on the viral particle binds to the CD4 receptor on the surface of T4 lymphocytes or other target cells. The bound virus merges with the target cell and reverse transcribes its
30 RNA genome into the double-stranded DNA of the cell. The viral DNA is incorporated into the genetic material in the cell's nucleus, where the viral DNA directs the production of new viral RNA, viral proteins, and

new virus particles. The new particles bud from the target cell membrane and infect other cells.

Destruction of T4 lymphocytes, which are critical to immune defense, is a major cause of the progressive immune dysfunction that is the hallmark of HIV infection. The loss of target cells seriously impairs the body's ability to fight most invaders, but it has a particularly severe impact on the defenses against viruses, fungi, parasites and certain bacteria, including mycobacteria.

HIV-1 kills the cells it infects by replicating, budding from them and damaging the cell membrane. HIV-1 may kill target cells indirectly by means of the viral gp120 that is displayed on an infected cell's surface. Since the CD4 receptor on T cells has a strong affinity for gp120, healthy cells expressing CD4 receptor can bind to gp120 and fuse with infected cells to form a syncytium.

HIV-1 can also elicit normal cellular immune defenses against infected cells. With or without the help of antibodies, cytotoxic defensive cells can destroy an infected cell that displays viral proteins on its surface. Finally, free gag and gp120 protein may circulate in the blood of individuals infected with HIV-1. The free gp120 protein may bind to the CD4 receptor of uninfected cells, making them appear to be infected and evoking an immune response.

Infection with HIV-1 is almost always fatal, and at present there are no cures for HIV-1 infection. Effective vaccines for prevention of HIV-1 infection are not yet available. Because of the danger of reversion or infection, live attenuated virus probably cannot be used as a vaccine. Most subunit vaccine approaches have not been successful at preventing HIV infection. Treatments for HIV-1 infection, while prolonging the lives of some infected persons, have serious side effects. There is thus a great need for effective treatments and vaccines to combat this lethal infection.

Vaccination is an effective form of disease prevention and has proven successful against several types of viral infection. Determining ways to present HIV-1 antigens to the human immune system in order to evoke protective humoral and cellular immunity, is a difficult task. To date, attempts to generate an effective HIV vaccine have not been successful. In AIDS patients, free virus is present in low levels only. Transmission of HIV-1 is enhanced by cell-to-cell

interaction via fusion and syncytia formation. Hence, antibodies generated against free virus or viral subunits are generally ineffective in eliminating virus-infected cells.

Vaccines exploit the body's ability to "remember" an antigen. After first encounters with a given antigen the immune system generates cells that retain an immunological memory of the antigen for an individual's lifetime. Subsequent exposure to the antigen stimulates the immune response and results in elimination or inactivation of the pathogen.

The immune system deals with pathogens in two ways: by humoral and by cell-mediated responses. In the humoral response lymphocytes generate specific antibodies that bind to the antigen thus inactivating the pathogen. The cell-mediated response involves cytotoxic and helper T lymphocytes that specifically attack and destroy infected cells.

Vaccine development with HIV-1 virus presents problems because HIV-1 infects some of the same cells the vaccine needs to activate in the immune system (i.e., T4 lymphocytes). It would be advantageous to develop a vaccine which inactivates HIV before impairment of the immune system occurs. A particularly suitable type of HIV vaccine would generate an anti-HIV immune response which recognizes HIV variants and which works in HIV-positive individuals who are at the beginning of their infection.

A major challenge to the development of vaccines against viruses, particularly those with a high rate of mutation such as the human immunodeficiency virus, against which elicitation of neutralizing and protective immune responses is desirable, is the diversity of the viral envelope proteins among different viral isolates or strains. Because cytotoxic T-lymphocytes (CTLs) in both mice and humans are capable of recognizing epitopes derived from conserved internal viral proteins, and are thought to be important in the immune response against viruses, efforts have been directed towards the development of CTL vaccines capable of providing heterologous protection against different viral strains.

It is known that CD8⁺ CTLs kill virally-infected cells when their T cell receptors recognize viral peptides associated with MHC class I molecules. The viral peptides are derived from endogenously

synthesized viral proteins, regardless of the protein's location or function within the virus. Thus, by recognition of epitopes from conserved viral proteins, CTLs may provide cross-strain protection. Peptides capable of associating with MHC class I for CTL recognition

5 originate from proteins that are present in or pass through the cytoplasm or endoplasmic reticulum. In general, exogenous proteins, which enter the endosomal processing pathway (as in the case of antigens presented by MHC class II molecules), are not effective at generating CD8⁺ CTL responses.

10 Most efforts to generate CTL responses have used replicating vectors to produce the protein antigen within the cell or have focused upon the introduction of peptides into the cytosol. These approaches have limitations that may reduce their utility as vaccines. Retroviral vectors have restrictions on the size and structure of

15 polypeptides that can be expressed as fusion proteins while maintaining the ability of the recombinant virus to replicate, and the effectiveness of vectors such as vaccinia for subsequent immunizations may be compromised by immune responses against the vectors themselves. Also, viral vectors and modified pathogens have inherent risks that may

20 hinder their use in humans. Furthermore, the selection of peptide epitopes to be presented is dependent upon the structure of an individual's MHC antigens and, therefore, peptide vaccines may have limited effectiveness due to the diversity of MHC haplotypes in outbred populations.

25 Benvenisty, N., and Reshef, L. [*PNAS* 83, 9551-9555, (1986)] showed that CaCl₂-precipitated DNA introduced into mice intraperitoneally (i.p.), intravenously (i.v.) or intramuscularly (i.m.) could be expressed. The i.m. injection of DNA expression vectors without CaCl₂ treatment in mice resulted in the uptake of DNA by the

30 muscle cells and expression of the protein encoded by the DNA. The plasmids were maintained episomally and did not replicate. Subsequently, persistent expression has been observed after i.m. injection in skeletal muscle of rats, fish and primates, and cardiac muscle of rats. The technique of using nucleic acids as therapeutic

35 agents was reported in WO90/11092 (4 October 1990), in which naked polynucleotides were used to vaccinate vertebrates.

It is not necessary for the success of the method that immunization be intramuscular. The introduction of gold microprojectiles coated with DNA encoding human growth hormone (HGH) into the skin of mice resulted in production of anti-HGH
5 antibodies in the mice. A jet injector has been used to transfect skin, muscle, fat, and mammary tissues of living animals. Various methods for introducing nucleic have been reviewed. Intravenous injection of a DNA:cationic liposome complex in mice was shown by Zhu et al., [Science 261:209-211 (9 July 1993) to result in systemic expression of a
10 cloned transgene. Ulmer et al., [Science 259:1745-1749, (1993)] reported on the heterologous protection against influenza virus infection by intramuscular injection of DNA encoding influenza virus proteins.

The need for specific therapeutic and prophylactic agents capable of eliciting desired immune responses against pathogens and
15 tumor antigens is met by the instant invention. Of particular importance in this therapeutic approach is the ability to induce T-cell immune responses which can prevent infections or disease caused even by virus strains which are heterologous to the strain from which the antigen gene was obtained. This is of particular concern when dealing
20 with HIV as this virus has been recognized to mutate rapidly and many virulent isolates have been identified [see, for example, LaRosa et al., Science 249:932-935 (1990), identifying 245 separate HIV isolates]. In response to this recognized diversity, researchers have attempted to generate CTLs based on peptide immunization. Thus, Takahashi et al.,
25 [Science 255:333-336 (1992)] reported on the induction of broadly cross-reactive cytotoxic T cells recognizing an HIV envelope (gp160) determinant. However, those workers recognized the difficulty in achieving a truly cross-reactive CTL response and suggested that there is a dichotomy between the priming or restimulation of T cells, which is
30 very stringent, and the elicitation of effector function, including cytotoxicity, from already stimulated CTLs.

Wang et al. reported on elicitation of immune responses in mice against HIV by intramuscular inoculation with a cloned, genomic (unspliced) HIV gene. However, the level of immune responses
35 achieved in these studies was very low. In addition, the Wang et al., DNA construct utilized an essentially genomic piece of HIV encoding contiguous Tat/rev-gp160-Tat/rev coding sequences. As is described in

detail below, this is a suboptimal system for obtaining high-level expression of the gp160. It also is potentially dangerous because expression of Tat contributes to the progression of Kaposi's Sarcoma.

WO 93/17706 describes a method for vaccinating an animal
5 against a virus, wherein carrier particles were coated with a gene construct and the coated particles are accelerated into cells of an animal. In regard to HIV, essentially the entire genome, minus the long terminal repeats, was proposed to be used. That method represents substantial risks for recipients. It is generally believed that constructs
10 of HIV should contain less than about 50% of the HIV genome to ensure safety of the vaccine; this ensures that enzymatic moieties and viral regulatory proteins, many of which have unknown or poorly understood functions have been eliminated. Thus, a number of problems remain if a useful human HIV vaccine is to emerge from the gene-delivery
15 technology.

The instant invention contemplates any of the known methods for introducing polynucleotides into living tissue to induce expression of proteins. However, this invention provides a novel immunogen for introducing HIV and other proteins into the antigen
20 processing pathway to efficiently generate HIV-specific CTLs and antibodies. The pharmaceutical is effective as a vaccine to induce both cellular and humoral anti-HIV and HIV neutralizing immune responses. In the instant invention, the problems noted above are addressed and solved by the provision of polynucleotide immunogens
25 which, when introduced into an animal, direct the efficient expression of HIV proteins and epitopes without the attendant risks associated with those methods. The immune responses thus generated are effective at recognizing HIV, at inhibiting replication of HIV, at identifying and killing cells infected with HIV, and are cross-reactive against many
30 HIV strains.

The codon pairings of organisms are highly nonrandom, and differ from organism to organism. This information is used to construct and express altered or synthetic genes having desired levels of translational efficiency, to determine which regions in a genome are
35 protein coding regions, to introduce translational pause sites into heterologous genes, and to ascertain relationship or ancestral origin of nucleotide sequences.

The expression of foreign heterologous genes in transformed organisms is now commonplace. A large number of mammalian genes, including, for example, murine and human genes, have been successfully inserted into single celled organisms. Standard techniques in this regard include introduction of the foreign gene to be expressed into a vector such as a plasmid or a phage and utilizing that vector to insert the gene into an organism. The native promoters for such genes are commonly replaced with strong promoters compatible with the host into which the gene is inserted. Protein sequencing machinery permits elucidation of the amino acid sequences of even minute quantities of native protein. From these amino acid sequences, DNA sequences coding for those proteins can be inferred. DNA synthesis is also a rapidly developing art, and synthetic genes corresponding to those inferred DNA sequences can be readily constructed.

Despite the burgeoning knowledge of expression systems and recombinant DNA, significant obstacles remain when one attempts to express a foreign or synthetic gene in an organism. Many native, active proteins, for example, are glycosylated in a manner different from that which occurs when they are expressed in a foreign host. For this reason, eukaryotic hosts such as yeast may be preferred to bacterial hosts for expressing many mammalian genes. The glycosylation problem is the subject of continuing research.

Another problem is more poorly understood. Often translation of a synthetic gene, even when coupled with a strong promoter, proceeds much less efficiently than would be expected. The same is frequently true of exogenous genes foreign to the expression organism. Even when the gene is transcribed in a sufficiently efficient manner that recoverable quantities of the translation product are produced, the protein is often inactive or otherwise different in properties from the native protein.

It is recognized that the latter problem is commonly due to differences in protein folding in various organisms. The solution to this problem has been elusive, and the mechanisms controlling protein folding are poorly understood.

The problems related to translational efficiency are believed to be related to codon context effects. The protein coding regions of genes

in all organisms are subject to a wide variety of functional constraints, some of which depend on the requirement for encoding a properly functioning protein, as well as appropriate translational start and stop signals. However, several features of protein coding regions have been discerned which are not readily understood in terms of these constraints. Two important classes of such features are those involving codon usage and codon context.

It is known that codon utilization is highly biased and varies considerably between different organisms. Codon usage patterns have been shown to be related to the relative abundance of tRNA isoacceptors. Genes encoding proteins of high versus low abundance show differences in their codon preferences. The possibility that biases in codon usage alter peptide elongation rates has been widely discussed. While differences in codon use are associated with differences in translation rates, direct effects of codon choice on translation have been difficult to demonstrate. Other proposed constraints on codon usage patterns include maximizing the fidelity of translation and optimizing the kinetic efficiency of protein synthesis.

Apart from the non-random use of codons, considerable evidence has accumulated that codon/anticodon recognition is influenced by sequences outside the codon itself, a phenomenon termed "codon context." There exists a strong influence of nearby nucleotides on the efficiency of suppression of nonsense codons as well as missense codons. Clearly, the abundance of suppresser activity in natural bacterial populations, as well as the use of "termination" codons to encode selenocysteine and phosphoserine require that termination be context-dependent. Similar context effects have been shown to influence the fidelity of translation, as well as the efficiency of translation initiation.

Statistical analyses of protein coding regions of E. coli demonstrate another manifestation of "codon context." The presence of a particular codon at one position strongly influences the frequency of occurrence of certain nucleotides in neighboring codons, and these context constraints differ markedly for genes expressed at high versus low levels. Although the context effect has been recognized, the predictive value of the statistical rules relating to preferred nucleotides adjacent to codons is relatively low. This has limited the utility of such

nucleotide preference data for selecting codons to effect desired levels of translational efficiency.

The advent of automated nucleotide sequencing equipment has made available large quantities of sequence data for a wide variety of organisms. Understanding those data presents substantial difficulties. For example, it is important to identify the coding regions of the genome in order to relate the genetic sequence data to protein sequences. In addition, the ancestry of the genome of certain organisms is of substantial interest. It is known that genomes of some organisms are of mixed ancestry. Some sequences that are viral in origin are now stably incorporated into the genome of eukaryotic organisms. The viral sequences themselves may have originated in another substantially unrelated species. An understanding of the ancestry of a gene can be important in drawing proper analogies between related genes and their translation products in other organisms.

There is a need for a better understanding of codon context effects on translation, and for a method for determining the appropriate codons for any desired translational effect. There is also a need for a method for identifying coding regions of the genome from nucleotide sequence data. There is also a need for a method for controlling protein folding and for insuring that a foreign gene will fold appropriately when expressed in a host. Genes altered or constructed in accordance with desired translational efficiencies would be of significant worth.

Another aspect of the practice of recombinant DNA techniques for the expression by microorganisms of proteins of industrial and pharmaceutical interest is the phenomenon of "codon preference". While it was earlier noted that the existing machinery for gene expression in genetically transformed host cells will "operate" to construct a given desired product, levels of expression attained in a microorganism can be subject to wide variation, depending in part on specific alternative forms of the amino acid-specifying genetic code present in an inserted exogenous gene. A "triplet" codon of four possible nucleotide bases can exist in 64 variant forms. That these forms provide the message for only 20 different amino acids (as well as transcription initiation and termination) means that some amino acids can be coded for by more than one codon. Indeed, some amino acids have as many as six "redundant", alternative codons while some others have a single,

required codon. For reasons not completely understood, alternative codons are not at all uniformly present in the endogenous DNA of differing types of cells and there appears to exist variable natural hierarchy or "preference" for certain codons in certain types of cells.

5 As one example, the amino acid leucine is specified by any of six DNA codons including CTA, CTC, CTG, CTT, TTA, and TTG (which correspond, respectively, to the mRNA codons, CUA, CUC, CUG, CUU, UUA and UUG). Exhaustive analysis of genome codon frequencies for microorganisms has revealed endogenous DNA of E. coli most commonly contains the CTG leucine-specifying codon, while the DNA of yeasts and slime molds most commonly includes a TTA leucine-specifying codon. In view of this hierarchy, it is generally held that the likelihood of obtaining high levels of expression of a leucine-rich polypeptide by an E. coli host will depend to some extent on the frequency of codon use. For example, a gene rich in TTA codons will in all probability be poorly expressed in E. coli, whereas a CTG rich gene will probably highly express the polypeptide. Similarly, when yeast cells are the projected transformation host cells for expression of a leucine-rich polypeptide, a preferred codon for use in an inserted DNA would be TTA.

20 The implications of codon preference phenomena on recombinant DNA techniques are manifest, and the phenomenon may serve to explain many prior failures to achieve high expression levels of exogenous genes in successfully transformed host organisms-a less "preferred" codon may be repeatedly present in the inserted gene and the host cell machinery for expression may not operate as efficiently. This phenomenon suggests that synthetic genes which have been designed to include a projected host cell's preferred codons provide a preferred form of foreign genetic material for practice of recombinant DNA techniques.

30 The diversity of function that typifies eukaryotic cells depends upon the structural differentiation of their membrane boundaries. To generate and maintain these structures, proteins must be transported from their site of synthesis in the endoplasmic reticulum to predetermined destinations throughout the cell. This requires that the trafficking proteins display sorting signals that are recognized by the molecular machinery responsible for route selection located at the access points to the main trafficking pathways. Sorting decisions for

most proteins need to be made only once as they traverse their biosynthetic pathways since their final destination, the cellular location at which they perform their function, becomes their permanent residence.

5 Maintenance of intracellular integrity depends in part on the selective sorting and accurate transport of proteins to their correct destinations. Over the past few years the dissection of the molecular machinery for targeting and localization of proteins has been studied vigorously. Defined sequence motifs have been identified on proteins
10 which can act as 'address labels'. Leader or signal peptides such as that from the tissue-specific plasminogen activator protein, tPA, serve to transport a protein into the cellular secretory pathway through the endoplasmic reticulum and golgi apparatus. A number of sorting signals have been found associated with the cytoplasmic domains of
15 membrane proteins such as di-Leucine amino acid motifs or tyrosine-based sequences that can direct proteins to lysosomal compartments. For HIV, transport and extrusion from the cell of viral particles depend upon myristoylation of glycine residue number two at the amino terminus of gag.

20

SUMMARY OF THE INVENTION

Synthetic DNA molecules encoding HIV *gag* and modifications of HIV *gag* are provided. The codons of the synthetic molecules include the projected host cell's preferred codons. The
25 synthetic molecules provide preferred forms of foreign genetic material. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against HIV infection through neutralizing antibody and cell-mediated immunity. This invention provides polynucleotides which, when directly introduced into a
30 vertebrate in vivo, including mammals such as primates and humans, induce the expression of encoded proteins within the animal.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the relative expression of gag and tPA gag
35 in 293 cell line transfectants after transfection with HIV *gag* DNA .

Figure 2 shows optimized HIV gag and tPA-gag DNA vaccine mediated serum anti-gag responses in mice.

Figure 3 shows anti-gag CTL responses of splenocytes obtained from mice following vaccination with optimized HIV gag or tPA-gag DNA.

Figure 4 shows gag antigen-specific cytokine secretion of
5 splenocytes obtained from mice following vaccination with optimized HIV gag or tPA-gag DNA.

Figure 5 shows anit-HIV gag CTL from mice vaccinated with HIV p55 gag DNAs.

10 DETAILED DESCRIPTION OF THE INVENTION

Synthetic DNA molecules encoding HIV *gag* and synthetic DNA molecules encoding modified forms of HIV *gag* are provided. The codons of the synthetic molecules are designed so as to use the codons preferred by the projected host cell. The synthetic molecules may be
15 used as a polynucleotide vaccine which provides effective immunoprophylaxis against HIV infection through neutralizing antibody and cell-mediated immunity. The synthetic molecules may be used as an immunogenic composition. This invention provides polynucleotides which, when directly introduced into a vertebrate in
20 vivo, including mammals such as primates and humans, induce the expression of encoded proteins within the animal.

As used herein, a polynucleotide is a nucleic acid which contains essential regulatory elements such that upon introduction into a living, vertebrate cell, it is able to direct the cellular machinery to
25 produce translation products encoded by the genes comprising the polynucleotide. In one embodiment of the invention, the polynucleotide is a polydeoxyribonucleic acid comprising at least one HIV gene operatively linked to a transcriptional promoter. In another embodiment of the invention, the polynucleotide vaccine (PNV)
30 comprises polyribonucleic acid encoding at least one HIV gene which is amenable to translation by the eukaryotic cellular machinery (ribosomes, tRNAs, and other translation factors). Where the protein encoded by the polynucleotide is one which does not normally occur in that animal except in pathological conditions, (i.e., a heterologous
35 protein) such as proteins associated with human immunodeficiency virus, (HIV), the etiologic agent of acquired immune deficiency syndrome, (AIDS), the animals' immune system is activated to launch a

protective immune response. Because these exogenous proteins are produced by the animals' tissues, the expressed proteins are processed by the major histocompatibility system, MHC, in a fashion analogous to when an actual infection with the related organism (HIV) occurs. The
5 result, as shown in this disclosure, is induction of immune responses against the cognate pathogen.

Accordingly, the instant inventors have prepared nucleic acids which, when introduced into the biological system induce the expression of HIV proteins and epitopes. The induced antibody response
10 is both specific for the expressed HIV protein, and neutralizes HIV. In addition, cytotoxic T-lymphocytes which specifically recognize and destroy HIV infected cells are induced.

The instant invention provides a method for using a polynucleotide which, upon introduction into mammalian tissue,
15 induces the expression in a single cell, in vivo, of discrete gene products. The instant invention provides a different solution which does not require multiple manipulations of *rev* dependent HIV genes to obtain *rev*-independent genes. The *rev*-independent expression system described herein is useful in its own right and is a system for
20 demonstrating the expression in a single cell in vivo of a single desired gene-product.

Because many of the applications of the instant invention apply to anti-viral vaccination, the polynucleotides are frequently referred to as a polynucleotide vaccine, or PNV. This is not to say that
25 additional utilities of these polynucleotides, in immune stimulation and in anti-tumor therapeutics, are considered to be outside the scope of the invention.

In one embodiment of this invention, a gene encoding an HIV gene product is incorporated in an expression vector. The vector
30 contains a transcriptional promoter recognized by an eukaryotic RNA polymerase, and a transcriptional terminator at the end of the HIV gene coding sequence. In a preferred embodiment, the promoter is the cytomegalovirus promoter with the intron A sequence (CMV-intA), although those skilled in the art will recognize that any of a number of
35 other known promoters such as the strong immunoglobulin, or other eukaryotic gene promoters may be used. A preferred transcriptional

terminator is the bovine growth hormone terminator. The combination of CMVintA-BGH terminator is particularly preferred.

To assist in preparation of the polynucleotides in prokaryotic cells, an antibiotic resistance marker is also preferably included in the expression vector under transcriptional control of a prokaryotic promoter so that expression of the antibiotic does not occur in eukaryotic cells. Ampicillin resistance genes, neomycin resistance genes and other pharmaceutically acceptable antibiotic resistance markers may be used. To aid in the high level production of the polynucleotide by fermentation in prokaryotic organisms, it is advantageous for the vector to contain a prokaryotic origin of replication and be of high copy number. A number of commercially available prokaryotic cloning vectors provide these benefits. It is desirable to remove non-essential DNA sequences. It is also desirable that the vectors not be able to replicate in eukaryotic cells. This minimizes the risk of integration of polynucleotide vaccine sequences into the recipients' genome. Tissue-specific promoters or enhancers may be used whenever it is desirable to limit expression of the polynucleotide to a particular tissue type.

In one embodiment, the expression vector pnRSV is used, wherein the Rous Sarcoma Virus (RSV) long terminal repeat (LTR) is used as the promoter. In another embodiment, V1, a mutated pBR322 vector into which the CMV promoter and the BGH transcriptional terminator were cloned is used. In another embodiment, the elements of V1 and pUC19 have been combined to produce an expression vector named V1J. Into V1J or another desirable expression vector is cloned an HIV gene, such as gp120, gp41, gp160, *gag*, *pol*, *env*, or any other HIV gene which can induce anti-HIV immune responses. In another embodiment, the ampicillin resistance gene is removed from V1J and replaced with a neomycin resistance gene, to generate V1J-neo into which different HIV genes have been cloned for use according to this invention. In another embodiment, the vector is V1Jns, which is the same as V1Jneo except that a unique Sfi1 restriction site has been engineered into the single Kpn1 site at position 2114 of V1J-neo. The incidence of Sfi1 sites in human genomic DNA is very low (approximately 1 site per 100,000 bases). Thus, this vector allows careful monitoring for expression vector integration into host DNA, simply by Sfi1 digestion of

extracted genomic DNA. In a further refinement, the vector is V1R. In this vector, as much non-essential DNA as possible was "trimmed" from the vector to produce a highly compact vector. This vector is a derivative of V1Jns. This vector allows larger inserts to be used, with
5 less concern that undesirable sequences are encoded and optimizes uptake by cells.

One embodiment of this invention incorporates genes encoding HIV *gag* from laboratory adapted strains of HIV such as IIIB or CAM-1. Those skilled in the art will recognize that the use of genes
10 from other strains of HIV-1 or HIV-2 strains having analogous function to the genes from HIV-1 would be expected to generate immune responses analogous to those described herein for HIV-1 constructs. The cloning and manipulation methods for obtaining these genes are known to those skilled in the art.

Sequences for many genes of many HIV strains are now publicly available on GENBANK and such primary, field isolates of HIV are available from the National Institute of Allergy and Infectious Diseases (NIAID) which has contracted with Quality Biological, Inc., [7581 Lindbergh Drive, Gaithersburg, Maryland 20879] to make these
20 strains available. Such strains are also available from the World Health Organization (WHO) [Network for HIV Isolation and Characterization, Vaccine Development Unit, Office of Research, Global Programme on AIDS, CH-1211 Geneva 27, Switzerland]. From this work those skilled in the art will recognize that one of the utilities of the instant invention is to provide a system for in vivo as well as in vitro testing and analysis so
25 that a correlation of HIV sequence diversity with serology of HIV neutralization, as well as other parameters can be made. Incorporation of genes from primary isolates of HIV strains provides an immunogen which induces immune responses against clinical isolates of the virus and thus meets a need as yet unmet in the field. Furthermore, as the virulent isolates change, the immunogen may be modified to reflect new sequences as necessary.

To keep the terminology consistent, the following convention is followed herein for describing polynucleotide immunogen
35 constructs: "Vector name-HIV strain-gene-additional elements". The additional elements that are added to the construct are described in further detail below. As the etiologic strain of the virus changes, the

precise gene which is optimal for incorporation in the pharmaceutical may be changed. However, as is demonstrated below, because CTL responses are induced which are capable of protecting against heterologous strains, the strain variability is less critical in the immunogen and vaccines of this invention, as compared with the whole virus or subunit polypeptide based vaccines. In addition, because the pharmaceutical is easily manipulated to insert a new gene, this is an adjustment which is easily made by the standard techniques of molecular biology.

10 The term "promoter" as used herein refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences
15 termed "silencers."

 The term "leader" as used herein refers to a DNA sequence at the 5' end of a structural gene which is transcribed along with the gene. The leader usually results in the protein having an N-terminal peptide extension sometimes called a pro-sequence. For proteins
20 destined for either secretion to the extracellular medium or a membrane, this signal sequence, which is generally hydrophobic, directs the protein into endoplasmic reticulum from which it is discharged to the appropriate destination.

 The term "intron" as used herein refers to a section of DNA
25 occurring in the middle of a gene which does not code for an amino acid in the gene product. The precursor RNA of the intron is excised and is therefore not transcribed into mRNA nor translated into protein.

 The term "cassette" refers to the sequence of the present invention which contains the nucleic acid sequence which is to be
30 expressed. The cassette is similar in concept to a cassette tape. Each cassette will have its own sequence. Thus by interchanging the cassette the vector will express a different sequence. Because of the restrictions sites at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

35 The term "3' untranslated region" or "3' UTR" refers to the sequence at the 3' end of a structural gene which is usually transcribed with the gene. This 3' UTR region usually contains the poly A sequence.

Although the 3' UTR is transcribed from the DNA it is excised before translation into the protein.

The term "Non-Coding Region" or "NCR" refers to the region which is contiguous to the 3' UTR region of the structural gene.

5 The NCR region contains a transcriptional termination signal.

The term "restriction site" refers to a sequence specific cleavage site of restriction endonucleases.

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There
10 are various types of vectors including plasmid, bacteriophages and cosmids.

The term "effective amount" means sufficient PNV is injected to produce the adequate levels of the polypeptide. One skilled in the art recognizes that this level may vary.

15 To provide a description of the instant invention, the following background on HIV is provided. The human immunodeficiency virus has a ribonucleic acid (RNA) genome. This RNA genome must be reverse transcribed according to methods known in the art in order to produce a cDNA copy for cloning and manipulation
20 according to the methods taught herein. At each end of the genome is a long terminal repeat which acts as a promoter. Between these termini, the genome encodes, in various reading frames, *gag-pol-env* as the major gene products: *gag* is the group specific antigen; *pol* is the reverse transcriptase, or polymerase; also encoded by this region, in an
25 alternate reading frame, is the viral protease which is responsible for post-translational processing, for example, of gp160 into gp120 and gp41; *env* is the envelope protein; *vif* is the virion infectivity factor; *rev* is the regulator of virion protein expression; *nef* is the negative regulatory factor; *vpu* is the virion productivity factor "u"; *tat* is the trans-activator
30 of transcription; *vpr* is the viral protein r. The function of each of these elements has been described.

In one embodiment of this invention, a gene encoding an HIV *gag* protein is directly linked to a transcriptional promoter. However, expression of *gag* is repressed in the absence of *rev* due to
35 non-export from the nucleus of non-spliced genes. For an understanding of this system, the life cycle of HIV must be described in further detail.

In the life cycle of HIV, upon infection of a host cell, HIV RNA genome is reverse-transcribed into a proviral DNA which integrates into host genomic DNA as a single transcriptional unit. The LTR provides the promoter which transcribes HIV genes from the 5' to 3' direction (*gag*, *pol*, *env*), to form an unspliced transcript of the entire genome. The unspliced transcript functions as the mRNA from which *gag* and *pol* are translated, while limited splicing must occur for translation of *env* encoded genes. For the regulatory gene product *rev* to be expressed, more than one splicing event must occur because in the genomic setting, *rev* and *env*, as is shown in figure 1, overlap. In order for transcription of *env* to occur, *rev* transcription must stop, and vice versa. In addition, the presence of *rev* is required for export of unspliced RNA from the nucleus. For *rev* to function in this manner, however, a *rev* responsive element (RRE) must be present on the transcript [Malim et al., *Nature* 338:254-257 (1989)].

In the polynucleotide vaccine of this invention, the obligatory splicing of certain HIV genes is eliminated by providing fully spliced genes (i.e.: the provision of a complete open reading frame for the desired gene product without the need for switches in the reading frame or elimination of noncoding regions; those of ordinary skill in the art would recognize that when splicing a particular gene, there is some latitude in the precise sequence that results; however so long as a functional coding sequence is obtained, this is acceptable). Thus, in one embodiment, the entire coding sequence for *gag* is spliced such that no intermittent expression of each gene product is required.

The dual humoral and cellular immune responses generated according to this invention are particularly significant to inhibiting HIV infection, given the propensity of HIV to mutate within the population, as well as in infected individuals. In order to formulate an effective protective vaccine for HIV it is desirable to generate both a multivalent antibody response for example to gp160 (*env* is approximately 80% conserved across various HIV-1, clade B strains, which are the prevalent strains in US human populations), the principal neutralization target on HIV, as well as cytotoxic T cells reactive to the conserved portions of gp160 and, internal viral proteins encoded by *gag*. We have made an HIV vaccine comprising gp160 genes selected from common laboratory strains; from predominant, primary

viral isolates found within the infected population; from mutated gp160s designed to unmask cross-strain, neutralizing antibody epitopes; and from other representative HIV genes such as the *gag* and *pol* genes (~95% conserved across HIV isolates).

5 Virtually all HIV seropositive patients who have not advanced towards an immunodeficient state harbor anti-*gag* CTLs while about 60% of these patients show cross-strain, gp160-specific CTLs. The amount of HIV specific CTLs found in infected individuals that have progressed on to the disease state known as AIDS, however, is
10 much lower, demonstrating the significance of our findings that we can induce cross-strain CTL responses.

 Immune responses induced by our *env* and *gag* polynucleotide vaccine constructs are demonstrated in mice and primates. Monitoring antibody production to *env* in mice allows
15 confirmation that a given construct is suitably immunogenic, i.e., a high proportion of vaccinated animals show an antibody response. Mice also provide the most facile animal model suitable for testing CTL induction by our constructs and are therefore used to evaluate whether a particular construct is able to generate such activity. Monkeys (African
20 green, rhesus, chimpanzees) provide additional species including primates for antibody evaluation in larger, non-rodent animals. These species are also preferred to mice for antisera neutralization assays due to high levels of endogenous neutralizing activities against retroviruses observed in mouse sera. These data demonstrate that sufficient
25 immunogenicity is engendered by our vaccines to achieve protection in experiments in a chimpanzee/HIVIIIB challenge model based upon known protective levels of neutralizing antibodies for this system. However, the currently emerging and increasingly accepted definition of protection in the scientific community is moving away from so-called
30 "sterilizing immunity", which indicates complete protection from HIV infection, to prevention of disease. A number of correlates of this goal include reduced blood viral titer, as measured by PCR, HIV reverse transcriptase activity, by infectivity of samples of serum, by ELISA assay of p24 or other HIV antigen concentration in blood, increased CD4⁺ T-
35 cell concentration, and by extended survival rates [see, for example, Cohen, J., *Science* 262:1820-1821, 1993, for a discussion of the evolving definition of anti-HIV vaccine efficacy]. The immunogens of the instant

invention also generate neutralizing immune responses against infectious (clinical, primary field) isolates of HIV.

An ELISA assay is used to determine whether optimized gag vaccine vectors expressing either secreted tPA-gag or native gag are efficacious for production of gag-specific antibodies. Initial in vitro characterization of gag expression by our vaccination vectors is provided by immunoblot analysis of optimized gag transfected cell lysates. These data confirm and quantitate gag expression using anti-HIV antisera to visualize transfectant cell gag expression.

Generation of CTL Responses. Viral proteins which are synthesized within cells give rise to MHC I-restricted CTL responses. Each of these proteins elicits CTL in seropositive patients. Our vaccines also are able to elicit CTL in mice and rhesus monkeys. The immunogenetics of mouse strains are conducive to such studies, as demonstrated with influenza NP, [see Ulmer et al., *Science* 259:1745-1749, 1993]. Several epitopes have been defined for the HIV proteins *env*, *rev*, *nef* and *gag* (Frankel, F.R., et al., *J. Immunol.* 155, 4775-82 (1995) in Balb/c mice, thus facilitating in vitro CTL culture and cytotoxicity assays. Alternatively, the entire gene encoding gp160, gp120, pol, or *gag* could be used. For additional review on this subject, see for example, (HIV Molecular Immunology Database 1995, Korber et al. eds., Los Alamos National Laboratory, Los Alamos, NM, USA). As used herein, T-cell effector function is associated with mature T-cell phenotype, for example, cytotoxicity, cytokine secretion for B-cell activation, and/or recruitment or stimulation of macrophages and neutrophils.

Measurement of TH Activities. Spleen cell cultures derived from vaccinated animals are tested for recall to specific antigens by addition of either recombinant protein or peptide epitopes. Activation of T cells by such antigens, presented by accompanying splenic antigen presenting cells, APCs, is monitored by proliferation of these cultures or by cytokine production. The pattern of cytokine production also allows classification of TH response as type 1 or type 2. Because dominant TH2 responses appear to correlate with the exclusion of cellular immunity in immunocompromised seropositive patients, it is possible to define the type of response engendered by a given PNV in patients, permitting manipulation of the resulting immune responses.

Based upon the above immunologic studies, it is predictable that our vaccines are effective in vertebrates against challenge by virulent HIV. These studies are accomplished in an HIV_{IIIB}/chimpanzee challenge model after sufficient vaccination of

5 these animals with a PNV construct, or a cocktail of PNV constructs comprised of gp160_{IIIB}, *gag*_{IIIB}, *nef*_{IIIB} and *REV*_{IIIB}. The IIIB strain is useful in this regard as the chimpanzee titer of lethal doses of this strain has been established. However, the same studies are envisioned using any strain of HIV and the epitopes specific to or

10 heterologous to the given strain. A second vaccination/challenge model, in addition to chimpanzees, is the *scid*-hu PBL mouse. This model allows testing of the human lymphocyte immune system and our vaccine with subsequent HIV challenge in a mouse host. This system is advantageous as it is easily adapted to use with any HIV strain and it

15 provides evidence of protection against multiple strains of primary field isolates of HIV. A third challenge model utilizes hybrid HIV/SIV viruses (SHIV), some of which have been shown to infect rhesus monkeys and lead to immunodeficiency disease resulting in death [see Li, J., et al., *J. AIDS* 5:639-646, 1992]. Vaccination of rhesus with our

20 polynucleotide vaccine constructs is protective against subsequent challenge with lethal doses of SHIV.

There are numerous viral and bacterially derived genes which do not utilize codons that are optimized for expression in mammalian cells. Reasons for this include the fact that these

25 microorganisms provide their own polymerases or provide specific proteins or factors to facilitate transcription/translation of their gene products. For bacteria, there may be different relative abundances for specific tRNAs. Clearly *in vivo* expression of such genes in the context of a DNA vaccine is substantially different.

30 Representative construct components include (but are not restricted to): HIV *env*, HIV *gag*, HIV *pol*, HIV *rev*, HIV *vpr*, and HIV *nef*. Genes encoding antigens expressed by pathogens other than HIV, such as, but not limited to, influenza virus nucleoprotein, hemagglutinin, matrix, neuraminidase, and other antigenic proteins;

35 herpes simplex virus genes; human papillomavirus genes; tuberculosis antigens; hepatitis A, B, or C virus antigens.

The protective efficacy of polynucleotide HIV immunogens against subsequent viral challenge is demonstrated by immunization with the non-replicating plasmid DNA of this invention. This is advantageous since no infectious agent is involved, assembly of virus particles is not required, and determinant selection is permitted. Furthermore, because the sequence of *gag* and protease and several of the other viral gene products is conserved among various strains of HIV, protection against subsequent challenge by a virulent strain of HIV that is homologous to, as well as strains heterologous to the strain from which the cloned gene is obtained, is enabled.

The invention offers a means to induce cross-strain protective immunity without the need for self-replicating agents or adjuvants. In addition, immunization with the instant polynucleotides offers a number of other advantages. This approach to vaccination should be applicable to tumors as well as infectious agents, since the CD8⁺ CTL response is important for both pathophysiological processes [K. Tanaka et al., *Annu. Rev. Immunol.* 6, 359 (1988)]. Therefore, eliciting an immune response against a protein crucial to the transformation process may be an effective means of cancer protection or immunotherapy. The generation of high titer antibodies against expressed proteins after injection of viral protein and human growth hormone DNA suggests that this is a facile and highly effective means of making antibody-based vaccines, either separately or in combination with cytotoxic T-lymphocyte vaccines targeted towards conserved antigens.

The ease of producing and purifying DNA constructs compares favorably with traditional methods of protein purification, thus facilitating the generation of combination vaccines. Accordingly, multiple constructs, for example encoding gp160, gp120, gp41, *gag*, or any other HIV gene may be prepared, mixed and co-administered. Because protein expression is maintained following DNA injection, the persistence of B- and T-cell memory may be enhanced, thereby engendering long-lived humoral and cell-mediated immunity.

Standard techniques of molecular biology for preparing and purifying DNA constructs enable the preparation of the DNA immunogens of this invention. While standard techniques of molecular biology are therefore sufficient for the production of the products of this

invention, the specific constructs disclosed herein provide novel polynucleotide immunogens which surprisingly produce cross-strain and primary HIV isolate neutralization, a result heretofore unattainable with standard inactivated whole virus or subunit protein
5 vaccines.

The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will depend on the strength of the transcriptional and translational promoters used and on the immunogenicity of the expressed gene product. In general, an
10 immunologically or prophylactically effective dose of about 1 ng to 100 mg, and preferably about 10 µg to 300 µg is administered directly into muscle tissue. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also
15 contemplated. It is also contemplated that booster vaccinations are to be provided. Following vaccination with HIV polynucleotide immunogen, boosting with HIV protein immunogens such as gp160, gp120, and *gag* gene products is also contemplated. Parenteral administration, such as intravenous, intramuscular, subcutaneous or other means of
20 administration of interleukin-12 protein, concurrently with or subsequent to parenteral introduction of the PNV of this invention is also advantageous.

The polynucleotide may be naked, that is, unassociated with any proteins, adjuvants or other agents which impact on the recipients' immune system. In this case, it is desirable for the polynucleotide to be
25 in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline. Alternatively, the DNA may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a DNA-liposome mixture, or the DNA may be
30 associated with an adjuvant known in the art to boost immune responses, such as a protein or other carrier. Agents which assist in the cellular uptake of DNA, such as, but not limited to, calcium ions, may also be used to advantage. These agents are generally referred to herein as transfection facilitating reagents and pharmaceutically
35 acceptable carriers. Techniques for coating microprojectiles coated with polynucleotide are known in the art and are also useful in connection with this invention.

The following examples are offered by way of illustration and are not intended to limit the invention in any manner.

EXAMPLE 1

5

Heterologous Expression of HIV Late Gene Products

HIV structural genes such as *env* and *gag* require expression of the HIV regulatory gene, *rev*, in order to efficiently produce full-length proteins. We have found that *rev*-dependent
10 expression of *gag* yielded low levels of protein and that *rev* itself may be toxic to cells. Although we achieved relatively high levels of *rev*-dependent expression of gp160 in vitro this vaccine elicited low levels of antibodies to gp160 following in vivo immunization with *rev*/gp160 DNA. This may result from known cytotoxic effects of *rev* as well as increased
15 difficulty in obtaining *rev* function in myotubules containing hundreds of nuclei (*rev* protein needs to be in the same nucleus as a *rev*-dependent transcript for *gag* or *env* protein expression to occur). However, it has been possible to obtain *rev*-independent expression using selected modifications of the *env* gene.

20 In general, our vaccines have utilized primarily HIV (IIIB, MN or CAM-1) *env* and *gag* genes for optimization of expression within our generalized vaccination vector, V1Jns, which is comprised of a CMV immediate-early (IE) promoter, BGH polyadenylation site, and a pUC backbone. Varying efficiencies, depending upon how large a gene
25 segment is used (e.g., gp120 vs. gp160), of *rev*-independent expression may be achieved for *env* by replacing its native secretory leader peptide with that from the tissue-specific plasminogen activator (tPA) gene and expressing the resulting chimeric gene behind the CMVIE promoter with the CMV intron A

30 As stated previously, we consider realization of the following objectives to be essential to maximize our chances for success with this program: (1) *env*-based vectors capable of generating stronger neutralizing antibody responses in primates; (2) *gag* and *env* vectors which elicit strong T-lymphocyte responses as characterized by CTL and
35 helper effector functions in primates; (3) use of *env* and *gag* genes from clinically relevant HIV-1 strains in our vaccines and characterization of

the immunologic responses, especially neutralization of primary isolates, they elicit; (4) demonstration of protection in an animal challenge model such as chimpanzee/HIV (IIIB) or rhesus/SHIV using appropriate optimized vaccines; and, (5) determination of the duration of immune responses appropriate to clinical use. Significant progress has been made on the first three of these objectives and experiments are in progress to determine whether our recent vaccination constructs for gp160 and *gag* will improve upon these initial results.

10

EXAMPLE 2

Vectors For Vaccine ProductionA. V1Jneo EXPRESSION VECTOR:

It was necessary to remove the amp^r gene used for antibiotic selection of bacteria harboring V1J because ampicillin may not be used in large-scale fermenters. The amp^r gene from the pUC backbone of V1J was removed by digestion with SspI and Eam1105I restriction enzymes. The remaining plasmid was purified by agarose gel electrophoresis, blunt-ended with T4 DNA polymerase, and then treated with calf intestinal alkaline phosphatase. The commercially available kan^r gene, derived from transposon 903 and contained within the pUC4K plasmid, was excised using the PstI restriction enzyme, purified by agarose gel electrophoresis, and blunt-ended with T4 DNA polymerase. This fragment was ligated with the V1J backbone and plasmids with the kan^r gene in either orientation were derived which were designated as V1Jneo #'s 1 and 3. Each of these plasmids was confirmed by restriction enzyme digestion analysis, DNA sequencing of the junction regions, and was shown to produce similar quantities of plasmid as V1J. Expression of heterologous gene products was also comparable to V1J for these V1Jneo vectors. We arbitrarily selected V1Jneo#3, referred to as V1Jneo hereafter, which contains the kan^r gene in the same orientation as the amp^r gene in V1J as the expression construct.

B. VIJns Expression Vector:

An Sfi I site was added to V1Jneo to facilitate integration studies. A commercially available 13 base pair Sfi I linker (New England BioLabs) was added at the Kpn I site within the BGH sequence of the vector. V1Jneo was linearized with Kpn I, gel purified, blunted by T4 DNA polymerase, and ligated to the blunt Sfi I linker. Clonal isolates were chosen by restriction mapping and verified by sequencing through the linker. The new vector was designated V1Jns. Expression of heterologous genes in V1Jns (with Sfi I) was comparable to expression of the same genes in V1Jneo (with Kpn I).

C. V1Jns-tPA:

In order to provide an heterologous leader peptide sequence to secreted and/or membrane proteins, V1Jn was modified to include the human tissue-specific plasminogen activator (tPA) leader. Two synthetic complementary oligomers were annealed and then ligated into V1Jn which had been BglII digested. These oligomers have overhanging bases compatible for ligation to BglII-cleaved sequences. After ligation the upstream BglII site is destroyed while the downstream BglII is retained for subsequent ligations. Both the junction sites as well as the entire tPA leader sequence were verified by DNA sequencing. Additionally, in order to conform with our consensus optimized vector V1Jns (=V1Jneo with an SfiI site), an SfiI restriction site was placed at the KpnI site within the BGH terminator region of V1Jn-tPA by blunting the KpnI site with T4 DNA polymerase followed by ligation with an SfiI linker (catalogue #1138, New England Biolabs). This modification was verified by restriction digestion and agarose gel electrophoresis.

D. Vector V1R Preparation:

In an effort to continue to optimize our basic vaccination vector, we prepared a derivative of V1Jns which was designated as V1R. The purpose for this vector construction was to obtain a minimum-sized vaccine vector, i.e., without unnecessary DNA sequences, which still retained the overall optimized heterologous gene expression characteristics and high plasmid yields that V1J and V1Jns afford. We determined from the literature as well as by experiment that (1) regions

within the pUC backbone comprising the *E. coli* origin of replication could be removed without affecting plasmid yield from bacteria; (2) the 3'-region of the *kan^r* gene following the kanamycin open reading frame could be removed if a bacterial terminator was inserted in its stead; and, 5 (3) ~300 bp from the 3'- half of the BGH terminator could be removed without affecting its regulatory function (following the original KpnI restriction enzyme site within the BGH element).

V1R was constructed by using PCR to synthesize three segments of DNA from V1Jns representing the CMVintA 10 promoter/BGH terminator, origin of replication, and kanamycin resistance elements, respectively. Restriction enzymes unique for each segment were added to each segment end using the PCR oligomers: SspI and XhoI for CMVintA/BGH; EcoRV and BamHI for the *kan^r* 15 gene; and, BclI and SalI for the *ori^r*. These enzyme sites were chosen because they allow directional ligation of each of the PCR-derived DNA segments with subsequent loss of each site: EcoRV and SspI leave blunt-ended DNAs which are compatible for ligation while BamHI and BclI leave complementary overhangs as do SalI and XhoI. After obtaining 20 these segments by PCR each segment was digested with the appropriate restriction enzymes indicated above and then ligated together in a single reaction mixture containing all three DNA segments. The 5'-end of the *ori^r* was designed to include the T2 rho independent terminator sequence that is normally found in this region so that it could provide termination information for the kanamycin resistance gene. The 25 ligated product was confirmed by restriction enzyme digestion (>8 enzymes) as well as by DNA sequencing of the ligation junctions. DNA plasmid yields and heterologous expression using viral genes within V1R appear similar to V1Jns. The net reduction in vector size achieved was 1346 bp (V1Jns = 4.86 kb; V1R = 3.52 kb).

30

EXAMPLE 3

Design of Synthetic Gene Segments for Increased *gag* Gene Expression:

Gene segments were converted to sequences having identical translated sequences but with alternative codon usage as 35 defined by R. Lathe in a research article from *J. Molec. Biol.* Vol. 183,

pp. 1-12 (1985) entitled "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations". The methodology described below to increase of expression of HIV *gag* gene segments was based on our hypothesis that the known inability to
5 express this gene efficiently in mammalian cells is a consequence of the overall transcript composition. Thus, using alternative codons encoding the same protein sequence may remove the constraints on expression of *gag*. The specific codon replacement method employed may be described as follows:

- 10 1. Identify placement of codons for proper open reading frame.
2. Compare wild type codon for observed frequency of use by human genes.
3. If codon is not the most commonly employed, replace
15 it with an optimal codon for high expression in human cells.
4. Repeat this procedure until the entire gene segment has been replaced.
5. Inspect new gene sequence for undesired sequences generated by these codon replacements (e.g., "ATTTA" sequences,
20 inadvertent creation of intron splice recognition sites, unwanted restriction enzyme sites, etc.) and substitute codons that eliminate these sequences.
6. Assemble synthetic gene segments and test for improved expression.

25 These methods were used to create the following synthetic gene segments for HIV *gag* creating a gene comprised entirely of optimal codon usage for expression. While the above procedure provides a summary of our methodology for designing codon-optimized genes for DNA vaccines, it is understood by one skilled in the art that similar
30 vaccine efficacy or increased expression of genes may be achieved by minor variations in the procedure or by minor variations in the sequence.

EXAMPLE 4

I. HIV gag Vaccine Constructs:

This is a complete HIV-1 (CAM1) gag orf comprised of optimal codons.

```

5      1  AGATCTACCA TGGGTGCTAG GGCTTCTGTG CTGTCTGGTG GTGAGCTGGA
      51  CAAGTGGGAG AAGATCAGGC TGAGGCCTGG TGGCAAGAAG AAGTACAAGC
      101 TAAAGCACAT TGTGTGGGCC TCCAGGGAGC TGGAGAGGTT TGCTGTGAAC
10     151 CCTGGCCTGC TGGAGACCTC TGAGGGGTGC AGGCAGATCC TGGGCCAGCT
      201 CCAGCCCTCC CTGCAAACAG GCTCTGAGGA GCTGAGGTCC CTGTACAACA
      251 CAGTGGCTAC CCTGTACTGT GTGCACCAGA AGATTGATGT GAAGGACACC
      301 AAGGAGGCCC TGGAGAAGAT TGAGGAGGAG CAGAACAAGT CCAAGAAGAA
      351 GGCCCAGCAG GCTGCTGCTG GCACAGGCAA CTCCAGCCAG GTGTCCCAGA
20     401 ACTACCCCAT TGTGCAGAAC CTCCAGGGCC AGATGGTGCA CCAGGCCATC
      451 TCCCCCGGA CCCTGAATGC CTGGGTGAAG GTGGTGGAGG AGAAGGCCTT
      501 CTCCCCTGAG GTGATCCCCA TGTTCCTGTC CCTGTCTGAG GGTGCCACCC
      551 CCCAGGACCT GAACACCATG CTGAACACAG TGGGGGGCCA TCAGGCTGCC
      601 ATGCAGATGC TGAAGGAGAC CATCAATGAG GAGGCTGCTG AGTGGGACAG
30     651 GCTGCATCCT GTGCACGCTG GCCCCATTGC CCCCAGCCAG ATGAGGGAGC
      701 CCAGGGGCTC TGACATTGCT GGCACCACCT CCACCCCTCA GGAGCAGATT
      751 GGCTGGATGA CCAACAACCC CCCCATCCCT GTGGGGGAAA TCTACAAGAG
      801 GTGGATCATC CTGGGCCTGA ACAAGATTGT GAGGATGTAC TCCCCACCT
      851 CCATCCTGGA CATCAGGCAG GGCCCCAAGG AGCCCTTCAG GGACTATGTG
40     901 GACAGGTTCT ACAAGACCCT GAGGGCTGAG CAGGCCTCCC AGGAGGTGAA
      951 GAACTGGATG ACAGAGACCC TGCTGGTGCA GAATGCCAAC CCTGACTGCA
      1001 AGACCATCCT GAAGGCCCTG GGCCCTGCTG CCACCCCTGGA GGAGATGATG
      1051 ACAGCCTGCC AGGGGGTGGG GGGCCCTGGT CACAAGGCCA GGGTGCTGGC
      1101 TGAGGCCATG TCCCAGGTGA CCAACTCCGC CACCATCATG ATGCAGAGGG
      1151 GCAACTTCAG GAACCAGAGG AAGACAGTGA AGTGCTTCAA CTGTGGCAAG
      1201 GTGGGCCACA TTGCCAAGAA CTGTAGGGCC CCCAGGAAGA AGGGCTGCTG
55     1251 GAAGTGTGGC AAGGAGGGCC ACCAGATGAA GGA CTGCAAT GAGAGGCAGG

```

1301 CCAACTTCCT GGGCAAAATC TGGCCCTCCC ACAAGGGCAG GCCTGGCAAC
 1351 TTCCTCCAGT CCAGGCCTGA GCCCAGAGCC CCTCCCGAGG AGTCCTTCAG
 5 1401 GTTTGGGGAG GAGAAGACCA CCCCCAGCCA GAAGCAGGAG CCCATTGACA
 1451 AGGAGCTGTA CCCCCTGGCC TCCCTGAGGT CCCTGTTTGG CAACGACCCC
 1501 TCCTCCCAGT AAAATAAAGC CCGGGCAGAT CT
 10 (SEQ ID NO:1)

EXAMPLE 5

In Vitro gag Vaccine Expression:

In vitro expression was tested in transfected human
 15 rhabdomyosarcoma (RD) or 293 cells for these constructs. Quantitation
 of gag from transfected 293 cells showed that V1Jns-opt-gag and V1Jns-
 tPA-opt gag vector produced secreted gag.

EXAMPLE 6

20

Assay For HIV-gag Cytotoxic T-Lymphocytes:

The methods described in this section illustrate the assay as
 used for vaccinated mice. An essentially similar assay can be used with
 primates except that autologous B cell lines must be established for use
 25 as target cells for each animal. This can be accomplished for humans
 using the Epstein-Barr virus and for rhesus monkey using the herpes B
 virus.

Peripheral blood mononuclear cells (PBMC) are derived
 from either freshly drawn blood or spleen using Ficoll-Hypaque
 30 centrifugation to separate erythrocytes from white blood cells. For mice,
 lymph nodes may be used as well. Effector CTLs may be prepared from
 the PBMC either by in vitro culture in IL-2 (20 U/ml) and concanavalin
 A (2µg/ml) for 6-12 days or by using specific antigen using an equal
 number of irradiated antigen presenting cells. Specific antigen can
 35 consist of either synthetic peptides (9-15 amino acids usually) that are
 known epitopes for CTL recognition for the MHC haplotype of the
 animals used, or vaccinia virus constructs engineered to express

appropriate antigen. Target cells may be either syngenic or MHC haplotype-matched cell lines which have been treated to present appropriate antigen as described for in vitro stimulation of the CTLs. For Balb/c mice the gag peptide of Paterson (J. Immunol., 1995), was
5 used at 10 μ M concentration to restimulate CTL in vitro using irradiated syngenic splenocytes and can be used to sensitize target cells during the cytotoxicity assay at 1-10 μ M by incubation at 37°C for about two hours prior to the assay. For these H-2^d MHC haplotype mice, the murine mastocytoma cell line, P815, provides good target cells. Antigen-
10 sensitized target cells are loaded with Na⁵¹CrO₄, which is released from the interior of the target cells upon killing by CTL, by incubation of targets for 1-2 hours at 37°C (0.2 mCi for $\sim 5 \times 10^6$ cells) followed by several washings of the target cells. CTL populations are mixed with target cells at varying ratios of effectors to targets such as 100:1, 50:1,
15 25:1, etc., pelleted together, and incubated 4-6 hours at 37°C before harvest of the supernatants which are then assayed for release of radioactivity using a gamma counter. Cytotoxicity is calculated as a percentage of total releasable counts from the target cells (obtained using 0.2% Triton X-100 treatment) from which spontaneous release
20 from target cells has been subtracted.

EXAMPLE 7

Assay For HIV gag Specific Antibodies:

ELISA were designed to detect antibodies generated against
25 HIV using either specific recombinant p24 gag protein as substrate antigens. 96 well microtiter plates were coated at 4°C overnight with recombinant antigen at 2 μ g/ml in PBS (phosphate buffered saline) solution using 50 μ l/well on a rocking platform. Antigens consisted of recombinant p24 gag (Intracell). Plates were rinsed four times using
30 wash buffer (PBS/0.05% Tween 20) followed by addition of 200 μ l/well of blocking buffer (1% Carnation milk solution in PBS/0.05% Tween-20) for 1 hr at room temperature with rocking. Pre-sera and immune sera were diluted in blocking buffer at the desired range of dilutions and 100 μ l added per well. Plates were incubated for 1 hr at room temperature
35 with rocking and then washed four times with wash buffer.

Secondary antibodies conjugated with horse radish peroxidase, (anti-rhesus Ig, Southern Biotechnology Associates; anti-mouse and anti-rabbit Igs, Jackson Immuno Research) diluted 1:2000 in blocking buffer, were then added to each sample at 100 µl/well and incubated 1 hr at
5 room temperature with rocking. Plates were washed 4 times with wash buffer and then developed by addition of 100 µl/well of an o-phenylenediamine (o-PD, Calbiochem) solution at 1 mg/ml in 100 mM citrate buffer at pH 4.5. Plates were read for absorbance at 450 nm both
10 kinetically (first ten minutes of reaction) and at 10 and 30 minute endpoints (Thermo-max microplate reader, Molecular Devices).

EXAMPLE 8

T Cell Proliferation Assays:

PBMCs are obtained and tested for recall responses to
15 specific antigen as determined by proliferation within the PBMC population. Proliferation is monitored using ³H-thymidine which is added to the cell cultures for the last 18-24 hours of incubation before harvest. Cell harvesters retain isotope-containing DNA on filters if
20 proliferation has occurred while quiescent cells do not incorporate the isotope which is not retained on the filter in free form. For either rodent or primate species 4 X 10⁵ cells are plated in 96 well microtiter plates in a total of 200 µl of complete media (RPMI/10% fetal calf serum). Background proliferation responses are determined using PBMCs and media alone while nonspecific responses are generated by using lectins
25 such as phytohaemagglutinin (PHA) or concanavalin A (ConA) at 1- 5 µg/ml concentrations to serve as a positive control. Specific antigen consists of either known peptide epitopes, purified protein, or inactivated virus. Antigen concentrations range from 1- 10 µM for peptides and 1-10 µg/ml for protein. Lectin-induced proliferation peaks at 3-5 days of cell
30 culture incubation while antigen-specific responses peak at 5-7 days. Specific proliferation occurs when radiation counts are obtained which are at least three-fold over the media background and is often given as a ratio to background, or Stimulation Index (SI).

EXAMPLE 9

The strategies we employ are designed to induce both cytotoxic T lymphocyte (CTL) and neutralizing antibody responses to HIV, principally directed at the HIV *gag* (~95% conserved) and *env* (gp160 or gp120; 70-80% conserved) gene products. gp160 contains the only known neutralizing antibody epitopes on the HIV particle while the importance of anti-*env* and anti-*gag* CTL responses are highlighted by the known association of the onset of these cellular immunities with clearance of primary viremia following infection, which occurs prior to the appearance of neutralizing antibodies (Koup et al., *J. Virol.* 68: 4650 (1994)), as well as a role for CTL in maintaining disease-free status. Although HIV is notorious for its genetic diversity we hope to obtain greater breadth of neutralizing antibodies both by including several representative *env* genes derived from clinical isolates and gp41 (~90% conserved; and contains the more conserved 2F5 neutralization epitope), while the highly conserved *gag* gene should generate broad cross-strain CTL responses. Because this vaccine strategy generates both strong humoral and cellular immunity against HIV (in nonhuman primates, this approach offers unique advantages compared to other available vaccination strategies for HIV.

A. HIV-1 *gag* Polynucleotide Vaccine Development:

Based upon our experiments for HIV *env* gene expression utilizing genes comprised of optimal codons for human expression, a synthetic p55 *gag* gene (opt *gag*) was designed and synthesized containing optimal codon usage throughout resulting in ~350 silent mutations (of 1500 nt total) and cloned into V1R. A second form of opt *gag* vector was also constructed which contained the sequence encoding the tPA signal peptide at the NH₂-terminus similar to that described above for HIV *env* and also eliminated a nuclear localization sequence motif located at this position in the wild type gene. This modification was designed to test whether altering the normal intracellular trafficking patterns for *gag* into the ER/golgi secretory pathway could alter the immunogenicity of the *gag* DNA vaccine. The addition of the tPA leader peptide to *gag* caused much higher levels of *gag* to be secreted and the secreted protein migrated as higher molecular weight form

compared to w.t. gag. This indicated that posttranslation modification, probably glycosylation, occurred as a result of modification with the tPA leader peptide.

Mice that had been immunized with either one of the two optimized p55 gag constructs (V1R-opt gag \pm tPA leader) or V1R-gag (wild-type) were tested for anti-gag peptide CTL responses following one injection (vaccination doses = 10, 3.3, or 1 μ g/mouse). High levels of anti-gag CTL were generated by both V1R-opt gag DNAs at all doses with V1R-tPA-opt gag giving the highest specific killing (~85% @ E/T = 3 with the 1 μ g dose). Comparison of cytotoxicity curves at each DNA doses demonstrated that V1R-tPA-opt gag vaccination produced ~100-fold stronger CTL responses than did V1R-gag (wild-type). Overall, immune responses for the three vaccine groups showed the same relative potencies for CTL, T help, and antibody responses (in order from greatest to lowest response): V1R-tPA-opt gag > V1R-opt gag > V1R gag (wild-type). In summary, CTL, humoral and helper T cell responses are much higher for the opt gag constructs, especially with a tPA leader.

20

EXAMPLE 10

Method of Treatment

A person in need of therapeutic or prophylactic immunization against infection with human immunodeficiency virus is injected with HIV DNA encoding all or part of the *env*, *gag* or *pol* genes or combinations thereof. The injection may be i.p., subcutaneous, intramuscular or intradermal. The HIV DNA may be used as a primer of the immune response or may be used as a booster of the immune response. The injection of DNA may antedate, coincide or follow injection of the person with a pharmaceutical composition comprising inactivated HIV, attenuated HIV, compositions comprising HIV-derived proteins, or combinations thereof.

30

EXAMPLE 11

Method of Treatment

5 A person in need of therapeutic treatment for infection with human immunodeficiency virus is treated with an anti-HIV antiviral agent or combinations thereof. The treated individual is injected with the HIV DNA pharmaceutical compositions of the instant disclosure.

WHAT IS CLAIMED IS:

1. A synthetic polynucleotide comprising a DNA sequence encoding a nonmammalian protein or fragment thereof, the DNA sequence comprising codons optimized for expression in a mammalian host.
 2. The polynucleotide of Claim 1 wherein the protein is selected from HIV proteins, HSV proteins, HAV proteins, HBV proteins, HCV proteins, HPV proteins, Plasmodium proteins, Mycobacterium proteins, Borrelia proteins and rotavirus proteins.
 3. The polynucleotide of Claim 2 wherein the protein is an HIV protein.
 4. The polynucleotide of Claim 3 having the following DNA sequence:
- ```

20 1 AGATCTACCA TGGGTGCTAG GGCTTCTGTG CTGTCTGGTG GTGAGCTGGA
 51 CAAGTGGGAG AAGATCAGGC TGAGGCCTGG TGGCAAGAAG AAGTACAAGC
 101 TAAAGCACAT TGTGTGGGCC TCCAGGGAGC TGGAGAGGTT TGCTGTGAAC
25 151 CCTGGCCTGC TGGAGACCTC TGAGGGGTGC AGGCAGATCC TGGGCCAGCT
 201 CCAGCCCTCC CTGCAAACAG GCTCTGAGGA GCTGAGGTCC CTGTACAACA
30 251 CAGTGGCTAC CCTGTACTGT GTGCACCAGA AGATTGATGT GAAGGACACC
 301 AAGGAGGCCC TGGAGAAGAT TGAGGAGGAG CAGAACAAGT CCAAGAAGAA
 351 GGCCCAGCAG GCTGCTGCTG GCACAGGCAA CTCCAGCCAG GTGTCCCAGA
35 401 ACTACCCCAT TGTGCAGAAC CTCCAGGGCC AGATGGTGCA CCAGGCCATC
 451 TCCCCCGGGA CCCTGAATGC CTGGGTGAAG GTGGTGGAGG AGAAGGCCTT
40 501 CTCCCCTGAG GTGATCCCCA TGTTCTCTGC CCTGTCTGAG GGTGCCACCC
 551 CCCAGGACCT GAACACCATG CTGAACACAG TGGGGGGCCA TCAGGCTGCC
 601 ATGCAGATGC TGAAGGAGAC CATCAATGAG GAGGCTGCTG AGTGGGACAG
45 651 GCTGCATCCT GTGCACGCTG GCCCCATTGC CCCCAGGCCAG ATGAGGGAGC
 701 CCAGGGGCTC TGACATTGCT GGCACCACCT CCACCCTCCA GGAGCAGATT

```

5 751 GGCTGGATGA CCAACAACCC CCCCATCCCT GTGGGGGAAA TCTACAAGAG  
 801 GTGGATCATC CTGGGCCTGA ACAAGATTGT GAGGATGTAC TCCCCACCT  
 851 CCATCCTGGA CATCAGGCAG GGCCCCAAGG AGCCCTTCAG GGACTATGTG  
 901 GACAGGTTCT ACAAGACCCT GAGGGCTGAG CAGGCCTCCC AGGAGGTGAA  
 10 951 GAACTGGATG ACAGAGACCC TGCTGGTGCA GAATGCCAAC CCTGACTGCA  
 1001 AGACCATCCT GAAGGCCCTG GGCCCTGCTG CCACCCTGGA GGAGATGATG  
 1051 ACAGCCTGCC AGGGGGTGGG GGGCCCTGGT CACAAGGCCA GGGTGCTGGC  
 15 1101 TGAGGCCATG TCCCAGGTGA CCAACTCCGC CACCATCATG ATGCAGAGGG  
 1151 GCAACTTCAG GAACCAGAGG AAGACAGTGA AGTGCTTCAA CTGTGGCAAG  
 20 1201 GTGGGCCACA TTGCCAAGAA CTGTAGGGCC CCCAGGAAGA AGGGCTGCTG  
 1251 GAAGTGTTGGC AAGGAGGGCC ACCAGATGAA GGACTGCAAT GAGAGGCAGG  
 1301 CCAACTTCCT GGGCAAAATC TGGCCCTCCC ACAAGGGCAG GCCTGGCAAC  
 25 1351 TTCCTCCAGT CCAGGCCTGA GCCCACAGCC CCTCCCGAGG AGTCCTTCAG  
 1401 GTTTGGGGAG GAGAAGACCA CCCCAGCCA GAAGCAGGAG CCCATTGACA  
 30 1451 AGGAGCTGTA CCCCCTGGCC TCCCTGAGGT CCCTGTTTGG CAACGACCCC  
 1501 TCCTCCCAGT AAAATAAAGC CCGGGCAGAT CT  
 (SEQ ID NO:1).

35 5. The polynucleotide of Claim 3 which induces anti-HIV neutralizing antibody, HIV specific T-cell immune responses, or protective immune responses upon introduction into vertebrate tissue, including human tissue *in vivo*, wherein the polynucleotide comprises a gene encoding an HIV *gag*, *gag*-protease, or *env* gene product,

40 6. A method for inducing immune responses in a vertebrate which comprises introducing between 1 ng and 100 mg of the polynucleotide of Claim 1 into the tissue of the vertebrate.

45 7. The method of Claim 6 which further comprises administration of attenuated pathogen, killed pathogen, subunit vaccines, protein vaccines and combinations thereof.

8. An immunogenic composition for inducing immune responses against HIV infection which comprises the polynucleotide of Claim 3 and a pharmaceutically acceptable carrier, and optionally, an adjuvant.

5

9. A method for inducing anti-HIV immune responses in a primate which comprises introducing the polynucleotide of Claim 3 into the tissue of said primate and concurrently administering a cytokine parenterally.

10

10. A method of inducing an antigen presenting cell to stimulate cytotoxic and helper T-cell proliferation and effector functions including lymphokine secretion specific to HIV antigens which comprises exposing cells of a vertebrate in vivo to the polynucleotide of Claim 3.

15

11. A method of treating a patient in need of such treatment comprising administering to the patient the polynucleotide of Claim 3 in combination with an anti-HIV antiviral agent.

20

12. A pharmaceutical composition comprising the polynucleotide of Claim 1.



1/5




FIG. 1

2/5




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4




FIG. 5

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C07K 14/16, C12N 15/49, 15/67,</b><br><b>A61K 48/00</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | <b>A3</b> | <b>(11) International Publication Number:</b> <b>WO 98/34640</b><br><br><b>(43) International Publication Date:</b> 13 August 1998 (13.08.98)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>(21) International Application Number:</b> PCT/US98/02293<br><br><b>(22) International Filing Date:</b> 3 February 1998 (03.02.98)<br><br><b>(30) Priority Data:</b><br>60/037,854 7 February 1997 (07.02.97) US<br>9705040.5 12 March 1997 (12.03.97) GB<br><br><b>(71) Applicant (for all designated States except US):</b> MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> SHIVER, John, W., Jr. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). DAVIES, Mary-Ellen, M. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). FREED, Daniel, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). LIU, Margaret, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PERRY, Helen, C. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).<br><br><b>(74) Common Representative:</b> MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). |           | <b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><br><b>(88) Date of publication of the international search report:</b><br>19 November 1998 (19.11.98) |
| <b>(54) Title:</b> SYNTHETIC HIV GAG GENES<br><br><b>(57) Abstract</b><br><br>Synthetic DNA molecules encoding HIV <i>gag</i> and modifications of HIV <i>gag</i> are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against HIV infection through stimulation of neutralizing antibody and cell-mediated immunity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                          |    |                                              |    |                          |
|----|--------------------------|----|------------------------------------------|----|----------------------------------------------|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |                                              | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali                                         | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger                                        | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |                                          | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan                                        |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 98/02293

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/16 C12N15/49 C12N15/67 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                             | Relevant to claim No. |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | WO 96 09378 A (THE GENERAL HOSPITAL CORP)<br>28 March 1996<br>see page 1 - page 26<br>see page 41                                                                                                                              | 1-3, 5,<br>10-12      |
| Y          | ----                                                                                                                                                                                                                           | 4, 6-9                |
| X          | HAAS J ET AL: "CODON USAGE LIMITATION IN<br>THE EXPRESSION OF HIV-1 ENVELOPE<br>GLYCOPROTEIN"<br>CURRENT BIOLOGY,<br>vol. 6, no. 3, 1 March 1996, GB,<br>pages 315-324, XP000619599<br>see the whole document<br>-----<br>-/-- | 1-3, 5,<br>10-12      |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"G" document member of the same patent family

Date of the actual completion of the international search

13 August 1998

Date of mailing of the international search report

27/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

De Kok, A



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/02293

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                      | Relevant to claim No. |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Y          | WO 94 16737 A (WEINER DAVID B ET AL) 4<br>August 1994<br>see page 2 - page 5<br>see page 14, line 29 - page 16, line 18<br>see page 32, line 25 - page 48, line 31<br>see page 94 - page 97                                                                                             | 6-9                   |
| A          | ----                                                                                                                                                                                                                                                                                    | 1,2,5                 |
| A          | WO 91 09869 A (MEDICAL RESEARCH COUNCIL )<br>11 July 1991<br>see the whole document                                                                                                                                                                                                     | 1-3,5,6,<br>8-12      |
| A          | ----<br>EP 0 565 794 A (BRITISH BIO-TECHNOLOGY) 20<br>October 1993<br>see column 1 - column 17                                                                                                                                                                                          | 1-3,5-12              |
| Y          | ----<br>EP 0 345 242 A (SMITHKLINE BIOLOGICALS ) 6<br>December 1989<br>see the whole document                                                                                                                                                                                           | 4                     |
| A          | ----<br>LIU M A ET AL: "Vaccination of mice and<br>nonhuman primates using<br>HIV-gene-containing DNA"<br>ANTIBIOTICS AND CHEMOTHERAPY,<br>vol. 48, 1996, BASEL CH,<br>pages 100-104, XP002073766<br>see the whole document                                                             | 1-12                  |
| P,X        | ----<br>WO 97 11086 A (THE GENERAL HOSPITAL CORP)<br>27 March 1997<br>see page 1 - page 20<br>see page 44                                                                                                                                                                               | 1-3,5,<br>10-12       |
| P,X        | ----<br>WO 97 31115 A (MERCK & CO INC) 28 August<br>1997<br>see the whole document                                                                                                                                                                                                      | 1-3,5-12              |
| P,X        | ----<br>ANDRE S ET AL: "Increased immune response<br>elicited by DNA vaccination with a<br>synthetic gp120 sequence with optimized<br>codon usage"<br>JOURNAL OF VIROLOGY.,<br>vol. 72, no. 2, February 1998, NEW YORK<br>US,<br>pages 1497-1503, XP002073767<br>see the whole document | 1-3,5-12              |
| E          | ----<br>WO 98 12207 A (THE GENERAL HOSPITAL CORP)<br>26 March 1998<br>see page 1 - page 2<br>see page 3, line 20 - line 23<br>see page 5, line 20 - page 6, line 3<br>see page 10, line 18 - page 21, line 18<br>see claims 1-4                                                         | 1-3,5,<br>10-12       |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In. ational Application No

PCT/US 98/02293

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO 9609378 A                              | 28-03-1996          | US 5786464 A               | 28-07-1998          |
|                                           |                     | AU 3509995 A               | 09-04-1996          |
|                                           |                     | CA 2200342 A               | 28-03-1996          |
|                                           |                     | EP 0781329 A               | 02-07-1997          |
|                                           |                     | JP 10506278 T              | 23-06-1998          |
| WO 9416737 A                              | 04-08-1994          | US 5593972 A               | 14-01-1997          |
|                                           |                     | AU 675702 B                | 13-02-1997          |
|                                           |                     | AU 6232094 A               | 15-08-1994          |
|                                           |                     | EP 0681483 A               | 15-11-1995          |
|                                           |                     | HU 73099 A                 | 28-06-1996          |
|                                           |                     | JP 8509694 T               | 15-10-1996          |
|                                           |                     | ZA 9400493 A               | 03-01-1995          |
| WO 9109869 A                              | 11-07-1991          | CA 2072351 A               | 06-07-1991          |
|                                           |                     | EP 0510054 A               | 28-10-1992          |
|                                           |                     | GB 2255093 A,B             | 28-10-1992          |
|                                           |                     | GB 2273709 A,B             | 29-06-1994          |
|                                           |                     | GB 2273710 A,B             | 29-06-1994          |
|                                           |                     | US 5700469 A               | 23-12-1997          |
|                                           |                     | US 5480967 A               | 02-01-1996          |
| EP 0565794 A                              | 20-10-1993          | AU 2462392 A               | 18-11-1993          |
|                                           |                     | AU 4076393 A               | 18-11-1993          |
|                                           |                     | CA 2118026 A               | 28-10-1993          |
|                                           |                     | WO 9320840 A               | 28-10-1993          |
|                                           |                     | WO 9321332 A               | 28-10-1993          |
|                                           |                     | JP 7505412 T               | 15-06-1995          |
|                                           |                     | NZ 244126 A                | 22-12-1994          |
|                                           |                     | ZA 9206340 A               | 21-02-1994          |
|                                           |                     | ZA 9302624 A               | 25-10-1993          |
| EP 0345242 A                              | 06-12-1989          | AP 129 A                   | 17-04-1991          |
|                                           |                     | AU 627465 B                | 27-08-1992          |
|                                           |                     | AU 3725689 A               | 03-01-1991          |
|                                           |                     | AU 4320689 A               | 06-02-1991          |
|                                           |                     | PT 90731 A                 | 29-12-1989          |
|                                           |                     | WO 9100904 A               | 24-01-1991          |
| WO 9711086 A                              | 27-03-1997          | EP 0851868 A               | 08-07-1998          |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/02293

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)  | Publication<br>date      |
|-------------------------------------------|---------------------|-----------------------------|--------------------------|
| WO 9731115 A                              | 28-08-1997          | AU 2124697 A<br>HR 970092 A | 10-09-1997<br>30-04-1998 |
| WO 9812207 A                              | 26-03-1998          | AU 4355697 A                | 14-04-1998               |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**